Warfarin prescription in patients with nonvalvular atrial fibrillation and one non –gender‐related risk factor (CHA2DS2VASc 1 or 2): A treatment dilemma
ConclusionWe found an elevated risk of major bleeding and intracranial hemorrhage in NVAF individuals treated with warfarin with 1 NGR risk factor for stroke. These data call for caution when treating with warfarin these individuals.
Source: Cardiovascular Therapeutics - Category: Cardiology Authors: Gentian Denas, Giacomo Zoppellaro, Seena Padayattil Jose, Emilia Antonucci, Francesco Marongiu, Daniela Poli, Sophie Testa, Armando Tripodi, Gualtiero Palareti, Vittorio Pengo Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
More News: Atrial Fibrillation | Bleeding | Cardiology | Cardiovascular | Coumadin | Heart | Hemorrhagic Stroke | Ischemic Stroke | Stroke | Study | Warfarin